Interim Safety Analysis or Re-Screening [Design Issues]

posted by professionalr – India, 2025-01-09 23:56 (181 d 08:37 ago) – Posting: # 24336
Views: 2,252

Hi all,

We are planning to conduct a bioequivalence study for submission in Egypt. The molecules of interest necessitate a washout period of approximately three months in a crossover design. Should we perform re-screening/interim safety analysis before the dosing of Period II?

Edit: Category changed; see also this post #1. [Helmut]
—
Thanks,
RP.

Complete thread:

UA Flag
Activity
 Admin contact
23,428 posts in 4,929 threads, 1,684 registered users;
75 visitors (0 registered, 75 guests [including 29 identified bots]).
Forum time: 09:33 CEST (Europe/Vienna)

To know that we know what we know,
and to know that we do not know what we do not know,
that is true knowledge.    Nicolaus Copernicus

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5